Back to top
more

Phibro Animal Health (PAHC)

(Real Time Quote from BATS)

$25.34 USD

25.34
200,063

+1.49 (6.25%)

Updated Nov 11, 2024 01:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks News

Investing in Phibro (PAHC)? Don't Miss Assessing Its International Revenue Trends

Explore Phibro's (PAHC) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls

Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.

TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket

Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

PAHC or ABT: Which Is the Better Value Stock Right Now?

PAHC vs. ABT: Which Stock Is the Better Value Option?

BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket

Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.

STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket

STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.

Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y

PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.

Zacks.com featured highlights include IAMGOLD, Leidos, Brinker International, Phibro Animal Health and State Street

AMGOLD, Leidos, Brinker International, Phibro Animal Health and State Street are part of the Zacks Screen of the Week article.

Phibro (PAHC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phibro Animal Health (PAHC) Tops Q1 Earnings Estimates

Phibro (PAHC) delivered earnings and revenue surprises of 52.17% and 6.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Vasundhara Sawalka headshot

5 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like IAG, LDOS, EAT, PAHC and STT are seeing price strength and have a high chance of carrying the momentum forward.

GMED Q3 Earnings Top, '24 Guidance Raised, Stock Gains in Aftermarket

Globus Medical delivers massive sales and earnings growth in the third quarter of 2024. However, margins contract.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket

Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.

ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

AdaptHealth Corp. (AHCO) Surpasses Q3 Earnings Estimates

AdaptHealth (AHCO) delivered earnings and revenue surprises of 5% and 0.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain DGX Stock in Your Portfolio Now

Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.

PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis

Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.

IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket

IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up

Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.

Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?

Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.